2026 ASTRO Presentations and Posters

Duke Radiation Oncology is proud to represent our Department during ASTRO 2026. Please click here to search Duke-authored presentations and posters from our faculty, trainees and staff or scroll down for a faculty and trainee listing of presentations and posters.

 

 

 

 

 

DateTimeTitlePresenter
Sept. 273-4 p.m.2227 - Outcomes Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Single Institution ExperienceAndrew Skipper, MD
Sept. 308-9 a.m.QP 39 - Imaging for Positioning and Motion ManagementAnna Rodrigues, PhD, MS
Sept. 293:45-5 p.m.EDU 51 - Mythbusting Radiation Oncology: Communicating the Truth and Value of Radiotherapy to the Public, Patients, Providers and PolicymakersAvinash Chaurasia, MD (adjunct)
Sept. 285:10-5:15 p.m.1092 - Coronary Artery Calcifications and Major Adverse Cardiac Events after Radiation Therapy for Locally-Advanced Non-Small Cell Lung CancerChristopher Kelsey, MD
Sept. 2912:30-1:45 p.m.ASTRO GI Guideline Session: Radiation Therapy for Gastric Cancer and Pancreatic Cancer: A Case-Based Interactive DiscussionChristopher Willett, MD
Sept. 309:15-10:30 a.m.SS 49 - Smart Planning and AdaptationChunhao Wang, PhD
Sept. 2912:30-1:45 p.m.EDU 38 - At the Margins: Navigating Challenging Vulvar and Vaginal CancersDiandra Ayala-Peacock, MD
Sept. 273-4 p.m.2230 - Efficacy and Safety of Fractionated Stereotactic Radiosurgery for the Treatment of Large Intracranial Arteriovenous MalformationsEugene Vaios, MD, MBA
Sept. 273-4 p.m.2241 - Neurocognitive Outcomes in Patients with Brain Metastases: A Systematic Review of Past Findings and Future DirectionsEugene Vaios, MD, MBA
Sept. 294:05-4:10 p.m.1143 - A Blood-based DNA Methylation Signature for Non-invasive Diagnosis and Prediction of Clinical Outcomes in Patients with Glioblastoma Enrolled on the Phase II Randomized VERTU TrialEugene Vaios, MD, MBA
Sept. 2810:45 a.m.-12 p.m.EDU 21 - Improving Communication to Enhance Patient Care in the Palliative SettingJared Robbins, MD
Sept. 295:20-5:25 p.m.1175 - Radiotherapy Dose De-Escalation in HPV-Associated Cancers of the Oropharynx Using Metabolic Signature from Interim 18FDG-PET/CTJared Robbins, MD
Sept. 275:20-5:30 p.m.145 - Federated Deep Ensemble Learning for MRI-Based Brain Metastasis Segmentation: An International Multi-Center DevelopmentJingtong Zhao, PhD
Sept. 2912:30-1:45 p.m.3009 - A Simple Motion Robust Planning Technique for Lung SBRTJohn Ginn, PhD
Sept. 292:15-3:30 p.m.3709 - Radiation Oncology Physician Workforce Populations: A Snapshot from the 2025 ASTRO Annual Member SurveyJoseph Salama, MD
Sept. 285:32-5:47 p.m.Closing the Loop: Using NLP and LLMs to Extract and Score Toxicities Post-RT to Drive Timely Interventions and Quality ImprovementJulian Hong, MD, MS (alumnus)
Sept. 2810:45 a.m.-12:15 p.m.EDU 24 - Comprehensive eContouring for GI, Head and Neck and Thoracic CancersManisha Palta, MD
Sept. 293:45-5 p.m.3469 - Prognostic Impact of Endobronchial Involvement in Ultracentral NSCLC Treated with Stereotactic Ablative RadiotherapyMarie Fort, MD
Sept. 288:02-8:17 a.m.Radiobiologic Mechanisms of Spatially Fractionated RT: Microenvironmental and Dose-Pattern EffectsMark Oldham, PhD
Sept. 295:40-5:45 p.m.1179 - Elective Nodal Irradiation to 44 Gy with Sequential IMRT Boost in HPV-Positive Oropharyngeal Squamous Cell CarcinomaMichael Chisam, MD (alumnus)
Sept. 293:15-3:25 p.m.Discussant (SS 34 - The Automated Clinic: AI-Powered Contouring, Monitoring, and Data Extraction)Q. Jackie Wu, PhD
Sept. 293:45-5 p.m.3462 - Stereotactic Body Radiation Therapy is Associated with Accelerated Pulmonary Fibrosis in Patients with Interstitial Lung Disease: A Comprehensive Radiologic AnalysisSeifallah Emam, MS (alumnus)
Sept. 283-4 p.m.2851 - Moderate Hypofractionated Radiation Therapy for Rosai-Dorfman DiseaseXavier Rodriguez-Lopez, MD, BS
Sept. 2912:30-1:45 p.m.3181 - Clinical Impact of Dynamic Collimator for Single-Isocenter Multi-Target SRS Evaluated through Physician Rating and Dosimetric AnalysisYibo Xie, PhD
Sept. 292:35-2:45 p.m.300 - A Novel Therapeutic Approach Using citVIM-specific CAR-T cells and Radiotherapy to Target NSCLC and Pancreatic Cancer CellsYorleny Vicioso Mora, MD, PhD, BS
Sept. 3010:45-11:45 a.m.QP 44 - Biology and Prevention of Radiation-Induced InjuryYvonne Mowery, MD, PhD, BS (alumnus)
Sept. 2912:30-1:45 p.m.SS 30 - Optimizing Therapy, Toxicity, and Supportive Care in Head & Neck CancersYvonne Mowery, MD, PhD, BS (alumnus)


 

Share